Guidelines on the management of acute myeloid leukaemia in adults

British Journal of Haematology

Volumn 135, Issue 4, 2006, Pages 450-474

  Milligan, D W ^a   Grimwade, D ^a   Cullis, J O ^a   Bond, L ^a   Swirsky, D ^a   Craddock, C ^a   Kell, J ^a   Homewood, J ^a   Campbell, K ^a   McGinley, S ^a   Wheatley, K ^a   Jackson, G ^a  

^a British Society for Haematology   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Acute promyelocytic leukaemia; Guidelines; Pregnancy; Transplantation

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CD14 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD64 ANTIGEN; CD7 ANTIGEN; CLOFARABINE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FIBRINOGEN; FLT3 LIGAND; FRESH FROZEN PLASMA; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; MERCAPTOPURINE; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; RETINOIC ACID; STEM CELL FACTOR RECEPTOR; TIOGUANINE; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; BIOPSY TECHNIQUE; BONE MARROW BIOPSY; CANCER CLASSIFICATION; CRYOPRECIPITATE; CYTOCHEMISTRY; DIFFERENTIAL DIAGNOSIS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPHENOTYPING; LEUKAPHERESIS; PARTIAL THROMBOPLASTIN TIME; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREPHINE BIOPSY;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PATIENT CARE TEAM; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS;

EID: 33750148809     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06314.x     Document Type: Review

References (181)

1. Ali, R., Ozkalemkas, F., Ozcelik, T., Ozkocaman, V., Ozan, U., Kimya, Y. & Tunali, A. (2003) Maternal and fetal outcomes in pregnancy complicated with acute leukemia: a single institutional experience with 10 pregnancies at 16 years. Leukemia Research, 27, 381-385.
2. AML Collaborative Group (1998) A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. British Journal of Haematology, 103, 100-109.
3. Anderson, J.E., Kopecky, K.J., Willman, C.L., Head, D., O'Donnell, M.R., Luthardt, F.W., Norwood, T.H., Chen, I.-M., Balcerzak, S.P., Johnson, D.B. & Appelbaum, F.R. (2002) Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood, 100, 3869-3876.
4. Artlich, A., Moller, J., Tschakaloff, A., Schwinger, E., Kruse, K. & Gortner, L. (1994) Teratogenic effects in a case of maternal treatment for acute myelocytic leukaemia-neonatal and infantile course. European Journal of Pediatrics, 153, 488-491.
5. Aversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., Reisner, Y. & Martelli, M.F. (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New England Journal of Medicine, 339, 1186-1193.
6. Aversa, F., Terenzi, A., Felicini, R., Carotti, A., Falcinelli, F., Tabilio, A., Velardi, A. & Martelli, M.F. (2002) Haploidentical stem cell transplantation for acute leukemia. International Journal of Hematology, 76(Suppl. 1), 165-168.
7. Avvisati, G., Lo Coco, F., Diverio, D., Falda, M., Ferrara, F., Lazzarino, M., Russo, D., Petti, M.C. & Mandelli, F. (1996) AIDA (All trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Pilot Study. Blood, 88, 1390-1398.
8. Avvisati, G., Petti, M.C., Lo Coco, F., Testi, A.M., Fazi, P., Specchia, G., Malagola, M., Di Bona, E., Recchia, A., Marmont, F., Buelli, M., Lazzarino, M., Di Raimondo, F., Leoni, F., Kropp, M.G., Vineri, D., Miccolis, I., Rossi, G., Venditti, A. & Mandelli, F. (2003) AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act. Blood, 102(Suppl. 1): 142a (abstract).
9. Baer, M.R., George, S.L., Dodge, R.K., O'Loughlin, K.L., Minderman, H., Caligiuri, M.A., Anastasi, J., Powell, B.L., Kolitz, J.E., Schiffer, C.A., Bloomfield, C.D. & Larson, R.A. (2002) Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukaemia: Cancer and Leukemia Group B Study 9720. Blood, 100, 1224-1232.
10. Baldus, C.D., Thiede, C., Soucek, S., Bloomfield, C.D., Thiel, E. & Ehninger, G. (2006) BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. Journal of Clinical Oncology, 24, 790-797.
11. Barjesteh van Waalwijk van Doorn-Khosravani, S., Erpelinck, C., van Putten, W.L., Valk, P.J., van der Poel-van de Luytgaarde, S., Hack, R., Slater, R., Smit, E.M., Beverloo, H.B., Verhoef, G., Verdonck, L.F., Ossenkoppele, G.J., Sonneveld, P., de Greef, G.E., Lowenberg, B. & Delwel, R. (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood, 101, 837-845.
12. Baudard, M., Marie, J.P., Cadiou, M., Viguie, F. & Zittoun, R. (1994) Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. British Journal of Haematology, 86, 82-91.
13. Bennett, J.M., Catovsky, D., Daniel, M.-T., Flandrin, G., Galton, D.A.G. & Sultan, C. (1985a) Proposed revised criteria for the classification of acute myeloid leukaemia. Annals of Internal Medicine, 103, 626-629.
14. Bennett, J.M., Catovsky, D., Daniel, M.-T., Flandrin, G., Galton, D.A.G. & Sultan, C. (1985b) Criteria for the diagnosis of acute leukaemia of megakaryocytic lineage (M7). A report of the French-American-British Cooperative Group. Annals of Internal Medicine, 103, 460-462.
15. Bennett, J.M., Catovsky, D., Daniel, M.-T., Flandrin, G., Galton, D.A.G. & Sultan, C. (1991) Proposals for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). British Journal of Haematology, 78, 325-329.
16. Bensinger, W.I., Martin, P.J., Storer, B., Clift, R., Forman, S.J., Negrin, R., Kashyap, A., Flowers, M.E.D., Lilleby, K., Chauncey, T.R., Storb, R. & Appelbaum, F.R. (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. New England Journal of Medicine, 344, 175-181.
17. Bergmann, L., Miething, C., Maurer, U., Brieger, J., Karakas, T., Weidmann, E. & Hoelzer, D. (1997) High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood, 90, 1217-1225.
18. Beutler, E., McMillan, R. & Spruce, W. (1982) The role of bone marrow transplantation in the treatment of acute leukemia in remission. Blood, 59, 1115-1117
19. Bishop, J.F., Lowenthal, P.M., Joshua, D., Matthews, J.P., Todd, D., Cobcroft, R., Whiteside, M.G., Kronenberg, H., Ma, D. & Dodds, A. (1990) Etoposide in acute non-lymphoblastic leukaemia. Blood, 75, 27-32.
20. Bishop, J.F., Matthews, J.P., Young, G.A., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M.M., Fox, R., Cobalt, R., Herrmann, R., Van Der Weyden, M., Lowenthal, R.M., Page, F., Garson, M.O. & Juneja, S. (1996) Randomized study of high-dose cytarabine in induction in acute myeloid leukaemia. Blood, 87, 1710-1717.
21. Breccia, M., Cimino, G., Alimena, G., De Carolis, S., Lo Coco, F. & Mandelli, F. (2002) AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation. Haematologica, 87, ELT12.
22. Breems, D.A., Wim, L.J., Huijgens, P.G., Ossenkoppele, G.J., Verhoef, L.F., Vellenga, E., De Greef, G.E., Jacky, E., Van der Lelie, J., Boogaerts, M. & Löwenberg, B. (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 23, 1969-1978.
23. British Committee for Standards in Haematology, Blood Transfusion Task Force (2003) Guidelines for the use of platelet transfusions. British Journal of Haematology, 122, 10-23
24. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G. & Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research, 7, 1490-1496.
25. Bunjes, D. (2001) The current status of T-cell depleted allogeneic stem-cell transplants in adult patients with AML. Cytotherapy, 3, 175-188.
26. Burnett, A.K. (2002) Acute myeloid leukemia: treatment of adults under 60 years. Reviews in Clinical and Experimental Hematology, 6, 26-45.
27. Burnett, A.K., Goldstone, A.H., Stevens, R.M.F., Hann, I.M., Rees, J.K.H., Gray, R.G. & Wheatley, K. (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid-leukaemia in first remission - results of MRC AML-10 trial. Lancet, 351, 700-708.
28. Burnett, A.K., Grimwade, D., Solomon, E., Wheatley, K. & Goldstone, A.H. (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood, 93, 4131-4143.
29. Burnett, A.K., Wheatley, K., Goldstone, A.H., Gibson, B., Webb, D., Prentice, A.G. & Milligan, D.W. (2002a) MRC AML12: a comparison of ADE vs MAE and S-DAT vs H-DAT ± retinoic acid for induction and four vs five total courses using chemotherapy or stem cell transplant in consolidation, in 3459 patients under 60 years with AML. Blood, 100, 582a.
30. Burnett, A.K., Wheatley, K., Goldstone, A.H., Stevens, R.F., Hann, I.M., Rees, J.H. & Harrison, G. (2002b) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 12 trial. British Journal of Haematology, 118, 385-400.
31. Burnett, A.K., Hills, R.K., Goldstone, A.H., Milligan, D., Prentice, A.G., Hann, I., Webb, D., Gibson, B. & Wheatley, K. (2004a) The impact of transplant in AML in 2nd CR: a prospective study of 741 in the MRC AML 10 and 12 trials. Blood, 104, 620a.
32. Burnett, A.K., Milligan, D., Prentice, A.G., Goldstone, A.H., McMullin, M.F. & Wheatley, K. (2004b) Low dose Ara-C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy: the UK NCRI AML14 trial. Blood, 104, 872a.
33. Byrd, J.C., Edenfield, W.J., Shields, D.J. & Dawson, N.A. (1995) Extramedullary myeloid cell tumours in acute nonlymphocytic leukemia: a review. Journal of Clinical Oncology, 13, 1800-1816.
34. Byrd, J.C., Weiss, R.B., Arthur, D.C., Lawrence, D., Baer, M.R., Davey, F., Trikha, E.S., Carroll, A.J., Tantravahi, R., Qumsiyeh, M., Patil, S.R., Moore, J.O., Mayer, R.J., Schiffer, C.A. & Bloomfield, C.D. (1997) Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. Journal of Clinical Oncology, 15, 466-475.
35. Cardonick, E. & Iacobucci, A. (2004) Use of chemotherapy during human pregnancy. Lancet Oncology, 5, 283-291.
36. Cartwright, R.A., Alexander, F.E., Mc Kinney, P.A. & Ricketts, T.J. (1990) Leukaemia and Lymphoma: An Atlas of Distribution within Areas of England and Wales 1984-88. Leukaemia Research Fund, London.
37. Cassileth, P.A., Harrington, D.P., Appelbaum, F.R., Lazarus, H.M., Rowe, J.M., Paietta, E., Willman, C., Hurd, D.D., Bennett, J.M., Blume, K.G., Head, D.R. & Wiernik, P. (1998) Chemotherapy compared with autologous or allogeneic transplantation in the management of acute myeloid leukaemia in first remission. New England Journal of Medicine, 339, 1649-1656.
38. Cheson, B.D. & Simon, R. (1987) Low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Seminars in Oncology, 14(Suppl. 1), 126-133.
39. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations for the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukaemia. Journal of Clinical Oncology, 21, 4642-4649.
40. Chomienne, C., Ballerini, P., Balitrand, N., Daniel, M.T., Fenaux, P., Castaigne, S. & Degos, L. (1990) All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood, 76, 1710-1717.
41. Clift, R.A., Buckner, C.D., Appelbaum, F.R., Schoch, G., Petersen, F.B., Bensinger, W.I., Sanders, J., Sullivan, K.M., Storb, R. & Singer, J. (1992) Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. Journal of Clinical Oncology, 10, 1723-1729.
42. De Botton, S., Fawaz, A., Chevret, S., Dombret, H., Thomas, X., Sanz, M., Guerci, A., San Miguel, J., de la Serna, J., Stoppa, A.M., Reman, O., Stamatoulas, A., Fey, M., Cahn, J.Y., Sotto, J.J., Bourhis, J.H., Parry, A., Chomienne, C., Degos, L. & Fenaux, P. (2005) Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European Acute Promyelocytic Leukemia Group. Journal of Clinical Oncology, 23, 120-126.
43. Detourmignies, L., Wattel, E., Lai, J.L., Bauters, F. & Fenaux, P. (1993) Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases. Annals of Hematology, 66, 235-240.
44. Diverio, D., Rossi, V., Avvisati, G., De Santis, S., Pistilli, A., Pane, F., Saglio, G., Martinelli, G., Petti, M.C., Santoro, A., Pelicci, P.G., Mandelli, F., Biondi, A. & Lo Coco, F. (1998) Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood, 92, 784-789.
45. Döhner, K., Tobis, K., Ulrich, R., Fröhling, S., Benner, A., Schlenk, R.F. & Döhner, H. (2002) Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. Journal of Clinical Oncology, 20, 3254-3261.
46. Döhner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rucker, F.G., Corbacioglu, A., Bullinger, L., Fröhling, S. & Döhner, H. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740-3746.
47. Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., Yver, A. & Degos, L. (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. New England Journal of Medicine, 332, 1678-1683.
48. Douer, D. & Tallman, M.S. (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. Journal of Clinical Oncology, 23, 2396-2410.
49. Douer, D., Hu, W., Giralt, S., Lill, M. & DiPersio, J. (2003) Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist, 8, 132-140.
50. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L.E., Koller, C. & Kornblau, S. (1994) Use of granulocyte-stimulating factor before during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparisons with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology, 12, 671-678.
51. Estey, E., Kornblau, S., Pierce, S., Kantarjian, H., Beran, M. & Keating, M. (1996) A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood, 88, 756-801.
52. Evans, G.D. & Grimwade, D. (1999) Extramedullary disease in acute promyelocytic leukemia. Leukemia & Lymphoma, 33, 219-229,
53. Falanga, A. & Rickles, F.R. (2003) Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Practice & Research. Clinical Haematology, 16, 463-482.
54. Falini, B., Flenghi, L., Fagioli, M., Lo Coco, F., Cordone, I., Diverio, D., Pasqualucci, L., Biondi, A., Riganelli, D., Orleth, A., Liso, A., Martelli, M.F., Pelicci, P.G. & Pileri, S. (1997) Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal-antibody PG-M3 (anti-PML). Blood, 90, 4046-4053.
55. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G., Martelli, M.F. & GIMEMA Acute Leukemia Working Party (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352, 254-266.
56. Feliu, J., Juarez, S., Ordonez, A., Garcia-Paredes, M.L., Gonzalez-Baron, M. & Montero, J.M. (1988) Acute leukemia and pregnancy. Cancer, 61, 580-584.
57. Fenaux, P., Le Deley, M.C., Castaigne, S., Archimbaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M.T., Bowen, D., Huebner, G., Bauters, F., Fegueux, N., Fey, M., Sanz, M., Lowenberg, B., Maloisel, F., Auzanneau, G., Sadoun, A., Gardin, C., Bastion, Y., Ganser, A., Jacky, E., Dombret, H., Chastang, C. & Degos, L. (1993) Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood, 82, 3241-3249-1200.
58. Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., Fey, M., Rayón, C., Huguet, F., Sotto, J.J., Gardin, C., Makhoul, P.C., Travade, P., Solary, E., Fegueux, N., Bordessoule, D., Miguel, J.S., Link, H., Desablens, B., Stamatoullas, A., Deconinck, E., Maloisel, F., Castaigne, S., Preudhomme, C. & Degos, L. (1999) A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood, 94, 1192-1200.
59. Ferrara, F. & Del Vecchio, L. (2002) Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity. Haematologica, 87, 306-319.
60. Firkin, F., Matthews, J., Bradstock, K. & Wiley, J.S. (1999) A phase II study of all-trans retinoic acid (ATRA) with prednisone prophylaxis in the treatment of acute promyelocytic leukemia (APL). Blood, 94(Suppl. 2), 228b (abstract).
61. Forman, S.J., Spruce, W.E., Farbstein, M.J., Wolf, J.L., Scott, E.P., Nademanee, A.P., Fahey, J.L., Hecht, T., Zaia, J.A., Krance, R.A., Findley, D.O. & Blume, K.G. (1983) Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. Blood, 61, 439-442.
62. Frassoni, F. (2000) Commentary and randomized studies in acute myeloid leukaemia: the double truth. Bone Marrow Transplantation, 25, 471-473.
63. Fröhling, S., Schlenk, R.F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H. & Döhner, K. (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. Journal of Clinical Oncology, 22, 624-633.
64. Fung, H.C., Stein, A., Slovak, M., O'donnell, M.R., Snyder, D.S., Cohen, S., Smith, D., Krishnan, A., Spielberger, R., Bhatia, R., Bhatia, S., Falk, P., Molina, A., Nademanee, A., Parker, P., Rodriguez, R., Rosenthal, J., Sweetman, R., Kogut, N., Sahebi, F., Popplewell, L., Vora, N., Somlo, G., Margolin, K., Chow, W., Smith, E. & Forman, S.J. (2003) A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biology of Blood and Marrow Transplantation, 9, 766-771.
65. Gale, R.P., Kay, H.E., Rimm, A.A. & Bortin, M.M. (1982) Bone-marrow transplantation for acute leukaemia in first remission. Lancet, 2, 1006-1009.
66. Gale, R.P., Buchner, T., Zang, M.J., Heinocke, A., Champlin, R.E., Dicke, K.A., Gluckman, E., Good, R.A., Gratwohl, A., Herzig, R.H., Keating, A., Klein, J.P., Marmont, A.M., Prentice, H.G., Rowlings, P.A., Sobocinski, K.A., Speck, B., Weiner, R.S. & Horowitz, M.M. (1996) HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia, 10, 1687-1691.
67. Gandhi, V., Kemena, A., Keating, M.J. & Plunkett, W. (1993) Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leukemia & Lymphoma, 10, 49-56.
68. Giles, F.J., Kantarjian, H.M., Kornblau, S.M., Thomas, D.A., Garcia-Manero, G., Waddelow, T.A., David, C.L., Phan, A.T., Colburn, D.E., Rashid, A., Estey, E.H. (2001) Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92, 406-413.
69. Godwin, J.E., Kopecky, K.J., Head, D.R., Willman, C.L., Leith, C.P., Hynes, H.E., Balcerzak, S.P. & Appelbaum, F.R. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood, 91, 3607-3615
70. Goldman, S.C., Holcenberg, J.S., Finklestein, J.Z., Hutchinson, R., Kreissman, S., Johnson, F.L., Tou, C., Harvey, E., Morris, E. & Cairo, M.S. (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 97, 2998-3003.
71. Goldstone, A.H., Burnett, A.K., Wheatley, K., Smith, A.G., Hutchinson, R.M. & Clark, R.E. (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood, 98, 1302-1311.
72. Goulden, N., Virgo, P. & Grimwade, D. (2006) Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now. British Journal of Haematology, 134, 273-282.
73. Grimwade, D. (1999) The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. British Journal of Haematology, 106, 591-613.
74. Grimwade, D. & Lo Coco, F. (2002) Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia, 16, 1959-1973.
75. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood, 92, 2322-2333.
76. Grimwade, D., Biondi, A., Mozziconacci, M.-J., Hagemeijer, A., Berger, R., Neat, M., Howe, K., Dastugue, N., Jansen, J., Radford-Weiss, I., Lo Coco, F., Lessard, M., Hernandez, J.-M., Delabesse, E., Head, D., Liso, V., Sainty, D., Flandrin, G., Solomon, E., Birg, F. & Lafage-Pochitaloff, M. (2000) Characterization of acute promyelocytic leukemia cases lacking the classical t(15;17): results of the European working party. Blood, 96, 1297-1308.
77. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C.J., Wheatley, K., Burnett, A.K. & Goldstone, A.J. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1312-1320.
78. Hann, I.M., Stevens, R.F., Goldstone, A., Rees, J.K.H., Wheatley, K., Gray, R.G. & Burnett, A.K. (1997) Randomized comparison of DAT versus ADE as induction chemotherapy in children and young adults with acute myeloid leukaemia. Results of the medical research council's 10th AML Trial (MRC AML 10). Blood, 89, 2311-2318.
79. Harousseau, J.L., Witz, B., Lioure, B., Hunault-Berger, M., Desablens, B., Delain, M., Guilhot, F., Le Prise, P.Y., Abgrall, J.F., Deconinck, E., Guyotat, D., Vilque, J.P., Casassus, P., Tournilhac, O., Audhuy, B. & Solary, E. (2000) Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. Journal of Clinical Oncology, 18, 780-787.
80. Harrousseau, J.L., Cahn, J.Y., Pignon, B., Witz, F., Milpied, N., Delain, M., Lioure, B., Lamy, T., Desablens, B., Guilhot, F., Caillot, D., Abgrall, J.-F., Francois, S., Briere, J., Guyotat, D., Casassus, P., Audhuy, B., Tellier, Z., Hurteloup, P. & Herve, P. (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as post-remission therapy in adult acute myeloid leukemia. The Group Ouese Est Leucemies Aigues Myeloblastiques (GOELAM). Blood, 90, 2978-2986.
81. Head, D., Kopecky, K.J., Weick, J., Files, J., Ryan, D., Foucar, K., Montiel, M., Bickers, J., Fishleder, A., Miller, M., Spier, C., Hanson, C., Bitter, M., Braziel, R., Mills, G., Welborn, J., Williams, W., Hewlett, J., Willman, C. & Appelbaum, F. (1995) Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood, 86, 1717-1728.
82. Heil, G., Hoelzer, D., Sanz, M.A., Lechner, K., Liu Yin, J.A., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., Matcham, J. & Barge, A. (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood, 90, 4710-4718.
83. Holmes, R., Keating, M.J., Cork, A., Broach, Y., Trujillo, J., Dalton, Jr, W.T., McCredie, K.B., Freireich, E.J. (1985) A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood, 65, 1071-1078.
84. Huang, M.-E., Ye, Y.-C., Chen, S.-R., Chai, J.-R., Lu, J.-X., Zhoa, L., Gu, L.-J. & Wang, Z.-Y. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567-572.
85. Jackson, G., Taylor, P., Smith, G.M., Marcus, R., Smith, A., Chu, P., Littlewood, T.,J., Duncombe, A., Hutchinson, M., Mehta, A.B., Johnson, S.A., Carey, P., Mackie, M.J., Ganly, P.S., Turner, G.E., Deane, M., Schey, S., Brookes, J., Tollerfield, S. & Wilson, M.P. (2001) A multicentre open non-comparative phase II study of a combination of fludarabine phosphate, cytarabine, granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. British Journal of Haematology, 112, 127-137.
86. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J. (2001) Tumours of Haematopoietic and Lymphoid Tissues. World Health Organisation Classification of Tumours. IARC Press, Lyon.
87. Kawamura, S., Yoshiike, M., Shimoyama, T., Suzuki, Y., Itoh, J., Yamagata, K., Fukushima, K., Ogasawara, H., Saitoh, S. & Tsushima, K. (1994) Management of acute leukemia during pregnancy: from the results of a nationwide questionnaire survey and literature survey. Tohoku Journal of Experimental Medicine, 174, 167-175.
88. Kell, W.J., Burnett, A.K., Chopra, R., Yin, J.A.L., Clark, R.E., Rohatiner, A., Culligan, D., Hunter, A., Prentice, A.G. & Milligan, D.W. (2003) A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood, 102, 4277-4283.
89. Kern, W., Schoch, C., Haferlach, T., Braess, J., Unterhalt, M., Wormann, B., Buchner, T. & Hiddemann, W. (2000) Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia, 14, 226-231.
90. Kerr, J.P., Liakopolou, E., Brown, J., Cornish, J.M., Fleming, D., Massey, E., Oakhill, A., Pamphilon, D.H., Robinson, S.P., Totem, A., Valencia, A.M. & Marks, D.I. (2003) The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. British Journal of Haematology, 123, 114-118.
91. Kersey, J.H., Ramsay, N.K., Kim, T., McGlave, P., Krivit, W., Levitt, S., Filipovich, A., Woods, W., O'Leary, M., Coccia, P. & Nesbit, M.E. (1982) Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia: a pilot study. Blood, 60, 400-403.
92. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
93. Kroger, N., Zabelina, T., Kruger, W., Renges, H., Stute, N., Rischewski, J., Sonnenberg, S., Ayuk, F., Togel, F., Schade, U., Fiegel, H., Erttmann, R., Loliger, C., Zander, A.R. (2002) in vivo T cell depletion with pre-transplant anti-thymocyte globulin reduces graft versus host disease without increasing relapse in good risk myeloid leukaemia patients from matched related donors. Bone Marrow Transplantation, 29, 683-689.
94. Langabeer, S.E., Walker, H., Gale, R.E., Wheatley, K., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (1997a) Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC adult leukaemia working party. British Journal of Haematology, 96, 736-739.
95. Langabeer, S.E., Walker, H., Rogers, J.R., Burnett, A.K., Wheatley, K., Swirsky, D., Goldstone, A.H. & Linch, D.C. (1997b) Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC adult leukaemia working party. British Journal of Haematology, 99, 925-928.
96. Larson, R.S. & Tallman, M.S. (2003) Retinoic acid syndrome: manifestations, pathogenesis and treatment. Best Practice & Research. Clinical Haematology, 16, 453-461.
97. Leith, C.P., Kopecky, K.J., Godwin, J., McConnell, T., Slovak, M.L., Chen, I.-M., Head, D.R., Appelbaum, F.R. & Willman, C.L. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 3323-3329.
98. Leith, C.P., Kopecky, K.J., Chen, I.M., Eijdems, L., Slovak, M.L., McConnell, T.S., Head, D.R., Weick, J., Grever, M.R., Appelbaum, F.R. & Willman, C.L. (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 94, 1086-1099.
99. Leoni, F., Gianfaldoni, G., Annunziata, M., Fanci, R., Ciolli, S., Nozzoli, C. & Ferrara, F. (2002) Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica, 87, 485-489.
100. Leopold, L.H. & Willemze, R. (2002) The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leukemia & Lymphoma, 43, 1715-1727.
101. Lo Coco, F., Diverio, D., Avvisati, G., Petti, M.C., Meloni, G., Pogliani, E.M., Biondi, A., Rossi, G., Carlo-Stella, C., Selleri, C., Martino, B., Specchia, G. & Mandelli, F. (1999) Therapy of molecular relapse in acute promyelocytic leukemia. Blood, 94, 2225-2229.
102. Lo Coco, F., Romano, A., Mengarelli, A., Diverio, D., Iori, A.P., Moleti, M.L., De Santis, S., Cerretti, R., Mandelli, F. & Arcese, W. (2003) Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia, 17, 1930-1933.
103. Lo Coco, F., Cimino, G., Breccia, M., Noguera, N.I., Diverio, D., Finolezzi, E., Pogliani, E.M., Di Bona, E., Micalizzi, C., Kropp, M., Venditti, A., Tafuri, A. & Mandelli, F. (2004) Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 104, 1995-1999.
104. Lowenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M., Solbu, G. & Suciu, S.,. (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. Journal of Clinical Oncology, 7, 1268-1274.
105. Lowenberg, B., Boogaerts, M. & Daenen, S. (1997a) Value of different modalities of granulocyte macrophage colony stimulating factor applied during or after induction therapy of acute myeloid leukemia. Journal of Clinical Oncology, 15, 3496-3506.
106. Lowenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G., Verhoef, G.E.G., Vellenga, E., Wijermans, P., Berneman, Z., Dekker, A.W., Stryckmans, P., Schouten, H., Jehn, U., Muus, P., Sonneveld, P., Dardenne, M. & Zittoun, R. (1997b) Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukaemia (AML): final report of AML-11, a phase III randomised study of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hemato-oncology Cooperative Group (HOVON). Blood, 90, 2952-2961.
107. Lowenberg, B., Suciu, S., Archimbaud, E., Haak, H., Stryckmans, P., de Cataldo, R., Dekker, A.W., Berneman, Z.N., Thyss, A., van der Lelie, J., Sonneveld, P., Visani, G., Fillet, G., Hayat, M., Hagemeijer, A., Solbu, G. & Zittoun, R. (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Journal of Clinical Oncology, 16, 872-881.
108. Lowenberg, B., van Putten, W., Theobald, M., Gmur, J., Verdonck, L., Sonneveld, P., Fey, M., Schouten, H., de Greef, G., Ferrant, A., Kovacsovics, T., Gratwohl, A., Daenen, S., Huijgens, P. & Boogaerts, M. (2003) Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. New England Journal of Medicine, 349, 743-752.
109. Marcucci, G., Baldus, C.D., Ruppert, A.S., Radmacher, M.D., Mrózek, K., Whitman, S.P., Kolitz, J.E., Edwards, C.G., Vardiman, J.W., Powell, B.L., Baer, M.R., Moore, J.O., Perotti, D., Caligiuri, M.A., Carroll, A.J., Larson, R.A., de la Chapelle, A. & Bloomfield, C.D. (2005) Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 23, 9234-9242.
110. Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R. & Frei, E. (1994) Intensive post-remission chemotherapy in adults with acute myeloid leukaemia. Cancer Leukaemia Group B. New England Journal of Medicine, 331, 896-903.
111. Meloni, G., Vignetti, M., Avvisati, G., Capria, S., Micozzi, A., Giona, F. & Mandelli, F. (1996) BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplantation, 18, 693-698.
112. Meloni, G., Diverio, D., Vignetti, M., Avvisati, G., Capria, S., Petti, M.C., Mandelli, F. & Lo Coco, F. (1997) Autologous bone-marrow transplantation for acute promyelocytic leukemia in 2nd remission - prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the pml/rar-alpha fusion gene. Blood, 90, 1321-1325.
113. Milligan, D.W., Wheatley, K., Littlewood, T., Craig, J.I., Burnett, A.K., NCRI Haematological Oncology Clinical Studies Group (2006) Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC-HR randomized trial. Blood, 107, 4614-4622.
114. Mistry, A.R., Wessel Pedersen, E., Solomon, E. & Grimwade, D. (2003) The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Reviews, 17, 71-97.
115. Murphy, M., Brown, M., Carrington, P., Hall, G., Jeffrey, R., Machin, S., Taylor, C. & Thomas, D. (2003) Guidelines for the use of platelet transfusion. British Journal of Haematology, 122, 10-23.
116. Murray, N.A., Acolet, D., Deane, M., Price, J. & Roberts, I.A. (1994) Fetal marrow suppression after maternal chemotherapy for leukaemia. Archives of Disease in Childhood. Fetal & Neonatal Edition, 71, F209-F210.
117. O'Connor, S.J., Forsyth, P.D., Dalal, S., Evans, P.A., Short, M.A., Schiach, C., Jack, A.S. & Morgan, G.J. (1997) The rapid diagnosis of acute promyelocytic leukaemia using PML (5E10) monoclonal antibody. British Journal of Haematology, 99, 597-604.
118. Ohno, R., Naoe, T., Kanamaru, A., Yoshida, M., Hiraoka, A., Kobayashi, T., Ueda, T., Minami, S., Morishima, Y. & Saito, Y. (1994) A double blind controlled study of granulocyte colony stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukaemia. Blood, 83, 2086-2092.
119. Orfao, A., Chillon, M.C., Bortolucci, A.M., Lopes-Berges, M.A., Garcia-Sanz, R., Gonzalez, M., Tabernero, M.D., Garcia-Marcos, M.A., Rasillo, A.I., Hernandez-Rivas, J. & San Miguel, J.F. (1999) The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARα gene rearrangements. Haematologica, 84, 405-412.
120. Ozer, H., Armitage, J.O., Bennett, C.L., Crawford, J., Demetri, G.D., Pizzo, P.A., Schiffer, C.A., Smith, T.J., Somlo, G., Wade, J.L., Winn, R.J., Wozniak, A.J., Somerfield, M.R., for ASCO growth factors expert panel. (2000) Update of recommendations for the use of haematopoietic colony-stimulating factors: evidence based, clinical practice guidelines. Journal of Clinical Oncology, 18, 3558-3585.
121. Pagliuca, A., Carrington, P., Pettengell, R., Rule, S., Keidan, J. & on behalf of the Haemato-Oncology Task Force of the British Committee for Standards in Haematology (2003) Guidelines on the use of colony-stimulating factors in haematological malignancies. British Journal of Haematology, 123, 22-33.
122. Papadopoulos, E.B., Carabasi, M.H., Castro-Malaspina, H., Childs, B.H., Mackinnon, S., Boulad, F., Gillio, A.P., Kernan, N.A., Small, T.N., Szabolcs, P., Taylor, J., Yahalom, J., Collins, N.A., Bleau, S.A., Black, P.M., Heller, G., O'Reilly, R.J. & Young, J.W. (1998) T cell depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft versus host disease. Blood, 91, 1083-1090.
123. Paul, M., Soares-Weiser, K., Grozinsky, S. & Leibovici, L. (2005) Beta-lactam Versus beta-Lactam-aminoglycoside Combination Therapy in Cancer Patients with Neutropenia (Cochrane Review) The Cochrane Library, Issue 1. John Wiley & Sons, Ltd, Chichester, UK.
124. Petti, M.C., Pinazzi, M.B., Diverio, D., Romano, A., Petrucci, M.T., De Santis, S., Meloni, G., Tafuri, A., Mandelli, F. & Lo Coco, F. (2001) Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). British Journal of Haematology, 115, 63-65.
125. Powell, B.L., Capizzi, R.L., Muss, H.B., Bearden, J.D., Lyerly, E.S., Rosenbaum, D.L., Morgan, T.M., Richards, F., Jackson, D.V. & White, D.R. (1989) Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia, 3, 23-28.
126. Powles, R., Sirohi, B. & Kulkarni, S. (2003) Investigation and management of hyperleukocytosis in adults. In: The Effective Prevention and Management of Common Complications of Induction Chemotherapy in Haematological Malignancy (ed. by R. Pinketon, A. Rohatiner & A. Miles), Ch. 3, pp. 33-50. Aesculapius Medical Press, St Bartholomews Hospital, London.
127. Preisler, H., Davis, R.B., Kirshner, J., Dupre, E., Richards,F.3d., Hoagland, H.C., Kopel, S., Levy, R.N., Carey, R. & Schulman, P. (1987) Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood, 69, 1441-1449.
128. Preudhomme, C., Sagot, C., Boissel, N., Cayuela, J.M., Tigaud, I., de Botton, S., Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., Fenaux, P. & Dombret, H. (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 100, 2717-2723.
129. Rebulla, P., Finazzi, G., Marangoni, F.,, Avvisati, G., Gugliotta, L., Tognoni, G., Barbui, T., Mandelli, F. & Sirchia, ?? (1997) The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. New England Journal of Medicine, 337, 1870-1875.
130. Rees, J.K., Gray, R.G., Swirsky, D. & Hayhoe, F.G. (1986) Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet, 2, 1236-1241.
131. Rees, J.K.H., Gray, R.G. & Wheatley, K. (1996) Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML 9 study. MRC Leukaemia in Adults Working Party. British Journal of Haematology, 94, 89-98.
132. Reisner, Y., Gur, H., Reich-Zeliger, S., Martelli, M.F. & Bachar-Lustig, E. (2003) Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells. Annals of the New York Academy of Sciences, 996, 72-79.
133. Reynoso, E.E., Shepherd, F.A., Messner, H.A., Farquharson, H.A., Garvey, M.B. & Baker, M.A. (1987) Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with longterm follow-up of children exposed in utero to chemotherapeutic agents. Journal of Clinical Oncology, 5, 1098-1106.
134. Rowe, J.M., Andersen, J.W., Mazza, J.J., Bennett, J.M., Paietta, E., Hayes, F.A., Oette, D., Cassileth, P.A., Stadtmauer, E.A. & Wiernik, P.H. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood, 86, 457-462.
135. Rowe, J.M., Neuberg, D., Friedenberg, W., Bennett, J.M., Paietta, E., Makary, A.Z., Liesveld, J.L., Abboud, C.N., Dewald, G., Hayes, F.A., Tallman, M.S., Wiernik, P.H. & Eastern Cooperative Oncology (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood, 103, 479-485.
136. Sainty, D., Liso, V., Cantú-Rajnoldi, A., Head, D., Mozziconacci, M.-J., Arnoulet, C., Benattar, L., Fenu, S., Mancini, M., Delabesse, E., Duchayne, E., Mahon, F.-X., Gutierrez, N., Birg, F., Biondi, A., Grimwade, D., Lafage-Pochitaloff, M., Hagemeijer, A. & Flandrin, G. (2000) A new morphological classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF-RARα rearrangements. Blood, 96, 1287-1296.
137. Sanz, M.A., Martín, G., Rayón, C., Esteve, J., González, M., Díaz-Mediavilla, J., Bolufer, P., Barragán, E., Terol, M.J., González, J.D., Colomer, D., Chillón, C., Rivas, C., Gómez, T., Ribera, J.M., Bornstein, R., Román, J., Calasanz, M.J., Arias, J., Álvarez, C., Ramos, F. & Debén, G. (1999) A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic-positive acute efficacy and reduced toxicity in newly diagnosed PML/RAR promyelocytic leukemia. Blood, 94, 3015-3021.
138. Sanz, M.A., Martín, G., González, M., León, A., Rayón, C., Rivas, C., Colomer, D., Amutio, E., Capote, F.J., Milone, G.A., de la Serna, J., Román, J., Barragán, E., Bergua, J., Escoda, L., Parody, R., Negri, S., Calasanz, M.J. & Bolufer, P. (2004a) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood, 103, 1237-1243.
139. Sanz, M.A., Vellenga, E., Rayón, C., Díaz-Mediavilla, J., Rivas, C., Amutio, E., Arias, J., Debén, G., Novo, A., Bergua, J., de la Serna, J., Bueno, J., Negri, S., Beltrán de Heredia, J.M. & Martín, G. (2004b) All-trans-retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood, 104, 3490-3493.
140. Sanz, M.A., Tallman, M.S. & Lo-Coco, F. (2005) The tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood, 105, 3019-3025.
141. Sayer, H.G., Kröger, M., Beyer, J., Kiehl, M., Klein, S.A., Schaefer-Eckart, K., Schwerdtfeger, R., Siegert, W., Runde, V., Theuser, C., Martin, H., Schetelig, J., Beelen, D.W., Fauser, A., Kienast, J., Höffken, K., Ehninger, G. & Bornhäuser, M. (2003) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplantation, 31, 1089-1095.
142. Schnittger, S., Kinkelin, U., Schoch, C., Heinecke, A., Haase, D., Haferlach, T., Buchner, T., Wormann, B., Hiddemann, W. & Griesinger, F. (2000) Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia, 14, 796-804.
143. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. & Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-3739.
144. Sierra, J., Storer, B., Hansen, J.A., Martin, P.J., Petersdorf, E.W., Woolfrey, A., Matthews, D., Sanders, J.E., Storb, R., Appelbaum, F.R. & Anasetti, C. (2000) Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplantation, 26, 397-404.
145. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., Van Dongen, J.J., Bernstein, I.D., Appelbaum, F.R., Mylotarg Study Group. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244-3254.
146. Stone, R.M. & Mayer, R.J. (1990) The unique aspects of acute promyelocytic leukemia. Journal of Clinical Oncology, 8, 1913-1921.
147. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L. & Schiffer, C.A. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. New England Journal of Medicine, 332, 1671-1677.
148. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P.P., Lee, E.J., Moore, J.O., Powell, B.L., Baer, M.R., Bloomfield, C.D. & Schiffer, C.A. (2001) Post-remission therapy in older patients with de novo acute myeloid leukaemia (AML): A randomised trial comparing mitozantrone/intermediate dose cytarabine with standard dose cytarabine (CALGB Study 8923). Blood, 98, 548-553.
149. Suciu, S., Mandelli, F., de Witte, T., Zittoun, R., Gallo, E., Labar, B., De Rosa, G., Belhabri, A., Giustolisi, R., Delarue, R., Liso, V., Mirto, S., Leone, G., Bourhis, J.H., Fioritoni, G., Jehn, U., Amadori, S., Fazi, P., Hagemeijer, A. & Willemze, R. (2003) Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood, 102, 1232-1240.
150. Swirsky, D.M. & Richards, S.J. (2001) Laboratory diagnosis of acute myeloid leukaemia. Bailliere's Best Practice & Research. Clinical Haematology, 14, 1-17.
151. Swirsky, D.M., Li, Y.S., Mathews, J.G., Flemans, R.J., Rees, J.K. & Hayhoe, F.G. (1984) 8;21 Chromosomal translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features. British Journal of Haematology, 56, 199-213.
152. Szydlo, R., Goldman, J.M., Klein, J.P., Gale, R.P., Ash, R.C., Bach, F.H., Bradley, B.A., Casper, J.T., Flomenberg, N., Gajewski, J.L., Gluckman, E., Henslee-Downey, P.J., Hows, J.M., Jacobsen, N., Kolb, H.J., Lowenberg, B., Masaoka, T., Rowlings, P.A., Sondel, P.M., van Bekkum, D.W., van Rood, J.J., Vowels, M.R., Zhang, M.J. & Horowitz, M.M. (1997) Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. Journal of Clinical Oncology, 15, 1767.
153. Takeshita, A., Ohno, R., Hirashima, K., Toyama, K., Okuma, M., Saito, H., Ikeda, Y., Tomonaga, M. & Asano, S. (1995) A randomized double-blind controlled study of recombinant human granulocyte colony-stimulating factor in patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. Rinsho Ketsueki. Japanese Journal of Clinical Hematology, 36, 606-614.
154. Tallman, M.S. & Kwaan, H.C. (1992) Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood, 79, 543-553.
155. Tallman, M.S., Hakimian, D., Shaw, J.M., Lissner, G.S., Russell, E.J., Variakojis, D. (1993) Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. Journal of Clinical Oncology, 11, 690-697.
156. Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C.D., Rowe, J.M. & Wiernik, P.H. (1997) All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine, 337, 1021-1028.
157. Tallman, M.S., Rowlings, P.A., Milone, G., Zhang, M.-J., Perez, W.S., Weisdorf, D., Keating, A., Gale, R.P., Geller, R.B., Laughlin, M.J., Lazarus, H.M., Luger, S.M., McCarthy, P.L., Rowe, J.M., Saez, R.A., Vowles, M.R. & Horowitz, M.M. (2000) Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood, 96, 1254-1258.
158. Tallman, M.S., Nabhan, C., Feusner, J.H. & Rowe, J.M. (2002) Acute promyelocytic leukemia: evolving therapeutic strategies. Blood, 99, 759-767.
159. Tallman, M.S., Lefèbvre, P., Baine, R.M., Shoji, M., Cohen, I., Green, D., Kwaan, H.C., Paietta, E. & Rickles, F.R. (2004) Effects of alltrans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. Journal of Thrombosis and Haemostasis, 2, 1341-1350.
160. Taussig, D.C., Davies, A.J., Cavenagh, J.D., Oakervee, H., Syndercombe-Court, D., Kelsey, S., Amess, J.A., Rohatiner, A.Z., Lister, T.A. & Barnett, M.J. (2003) Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. Journal of Clinical Oncology, 21, 3060-3065.
161. Tilly, H., Castaigne, S., Bordessoule, D., Casassus, P., Le Prise, P.Y., Tertian, G., Desablens, B., Henry-Amar, M. & Degos, L. (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. Journal of Clinical Oncology, 8, 272-279.
162. Tomas, F., Gomez-Garcia de Soria, V., Lopez-Lorenzo, J.L., Arranz, R., Figuera, A., Camara, R., Alegre, A. & Fernandez-Ranada, J.M. (1996) Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome. Bone Marrow Transplantation, 17, 979-984.
163. Usuki, K., Urabe, A., Masaoka, T., Ohno, R., Mizoguchi, H., Hamajima, N., Miyazaki, T., Niitsu, Y., Yoshida, Y., Miura, A., Shibata, A., Abe, T., Miura, Y., Ikeda, Y., Nomura, T., Nagao, T., Saitou, H., Shirakawa, S., Ohkuma, M., Matsuda, T., Nakamura, T., Horiuchi, A., Kuramoto, A., Kimura, I., Irino, S., Niho, Y., Takatsuki, K., Tomonaga, M., Uchino, H. & Takaku, F. (2002) Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. British Journal of Haematology, 116, 103-112.
164. Vahdat, L., Maslak, P., Miller, W.H., Eardley, A., Heller, G., Scheinberg, D.A. & Warrell, R.P. (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML-RARα isoform, and CD13 expression in patients treated with All-trans retinoic acid. Blood, 84, 3843-3849.
165. Verhaak, R.G., Goudswaard, C.S., van Putten, W., Bijl, M.A., Sanders, M.A., Hugens, W., Uitterlinden, A.G., Erpelinck, C.A., Delwel, R., Lowenberg, B. & Valk, P.J. (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood, 106, 3747-3754.
166. Voak, D., Chapman, J., Finney, K., Forman, K., Kelsey, P., Knowles, S.M., Napier, J.F., Phillips, P., Mitchell, R., Murphy, M.F., Waters, A.H. & Wood, J.K. (1996) Guidelines for gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfusion Medicine, 6, 261-271.
167. Watson, M., Wheatley, K., Harrison, G.A., Zittoun, R., Gray, R.G., Goldstone, A.H. & Burnett, A.K. (1999) Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer, 86, 1231-1239.
168. Watson, M., Buck, G., Wheatley, K., Homewood, J.R., Goldstone, A.H., Rees, J.K. & Burnett, A.K. (2004) UK Medical Research Council AML 10 trial. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. Randomized Controlled Trial. European Journal of Cancer, 40, 971-978.
169. Weick, J.K., Kopecky, K.J., Appelbaum, F.R., Head, D.R., Kingsbury, L.L., Balcerzak, S.P., Bickers, J.N., Hynes, H.E., Welborn, J.L., Simon, S.R. & Grever, M. (1996) A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood, 88, 2841-2851,
170. Weltermann, A., Fonatsch, C., Haas, O.A., Greinix, H.T., Kahls, P., Miterbauer, G., Jager, U., Geissler, K., Valent, P., Sperr, W., Knobl, P., Schwarzinger, I., Gleiss, A. & Lechner, K. (2004) Impact of Cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia, 18, 293-302.
171. Wheatley, K. (2002) Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - A statistician's view. British Journal of Haematology, 118, 353-356.
172. Wheatley, K., Burnett, A.K., Goldstone, A.H., Gray, R.G., Hann, I.M., Harrison, C.J., Rees, J.K., Stevens, R.F. & Walker, H. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. British Journal of Haematology, 107, 69-79.
173. Whittaker, J.A., Sommerfield, G.P., Clough, J.V., Franklin, I.M., Gibson, B.E.S., Gorst, D.W., Murphy, M.F., Smith, J.G., Thomas, J.S. & Wood, J.K. (1995) British Committee for Standards in Haematology guidelines on he provision of facilities for the care of adult patients with haematological malignancies. Clinical and Laboratory Haematology, 17, 3-10.
174. Wiley, J.S. & Firkin, F.C. (1995) Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia, 9, 774-778.
175. Witz, F., Sadoun, A., Perrin, M.C., Berthou, C., Briere, J., Cahn, J.Y., Lioure, B., Witz, B., Francois, S., Desablens, B., Pignon, B., Le Prise, P.Y., Audhuy, B., Caillot, D., Casassus, P., Delain, M., Christian, B., Tellier, Z., Polin, V., Hurteloup, P. & Harousseau, J.L. (1998) A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood, 91, 2722-2730.
176. Wong, R., Giralt, S.A., Martin, T., Couriel, D.R., Anagnostopoulos, A., Hosing, C., Andersson, B.S., Cano, P., Shahjahan, M., Ippoliti, C., Estey, E.H., McMannis, J., Gajewski, J.L., Champlin, R.E. & de Lima, M. (2003) Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood, 102, 3052-3059.
177. Yin, J. & Grimwade, D. (2002) Minimal residual disease evaluation in acute myeloid leukaemia. Lancet, 360, 160-162.
178. Yin, J.A., Wheatley, K., Rees, J.K. & Burnett, A.K. (2001) Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical research Council AML-R trial. British Journal of Haematology, 122, 164-165.
179. Zittoun, R.A., Mandelli, F., Willemze, R., de Witte, T., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G., Papa, G., Caronia, F., Hayat, M., Stryckmans, P., Rotoli, B., Leoni, P., Peetermans, M.E., Dardenne, M., Vegna, M.L., Petti, M.C., Solbu, G. & Suciu, S. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. EORTC and GIMEMA groups. New England Journal of Medicine, 332, 217-223.
180. Zittoun, R., Suciu, S., Mandelli, F., de Witte, T., Thaler, J., Stryckmans, P., Hayat, M., Peetermans, M., Cadiou, M., Solbu, G., Petti, M.C. & Willemze, R. (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. Journal of Clinical Oncology, 14, 2150-2159.
181. Zittoun, R., Suciu, S., Watson, M., Solbu, G., Muus, P., Mandelli, F., Stryckmans, P., Peetermans, M., Thaler, J., Resegotti, L., Dardenne, M. & Willemze, R. (1997) Quality of life in patients with acute myelogenous leukaemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplantation, 20, 307-315.